Cargando…
Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice due to the simple and...
Autores principales: | Posocco, Bianca, Buzzo, Mauro, Poetto, Ariana Soledad, Orleni, Marco, Gagno, Sara, Zanchetta, Martina, Iacuzzi, Valentina, Guardascione, Michela, Puglisi, Fabio, Basile, Debora, Pelizzari, Giacomo, Marangon, Elena, Toffoli, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006908/ https://www.ncbi.nlm.nih.gov/pubmed/32032379 http://dx.doi.org/10.1371/journal.pone.0228822 |
Ejemplares similares
-
Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients
por: Iacuzzi, Valentina, et al.
Publicado: (2019) -
A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring
por: Zanchetta, Martina, et al.
Publicado: (2021) -
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023) -
Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
por: Turković, Lu, et al.
Publicado: (2022) -
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer
por: Roncato, Rossana, et al.
Publicado: (2022)